Support the project to create a Chair in Chemogenomics

When research translates into therapeutic solutions benefiting patients

About 20,000 new cases of acute myeloid leukemia (AML) are diagnosed every year in North America.

To this day, the majority of AML patients will die within two years of diagnosis. Only 27% of them will survive past the five-year mark. Therefore, there is an urgent need to develop new therapeutic strategies for those patients.

Specializing in bone marrow stem cell transplants and in the study of the molecular mechanisms involved in their self-renewal, Dr. Sauvageau, Principal Investigator at the IRIC and Hematologist at the Maisonneuve-Rosemont Hospital, is intent on being a game-changer.

The work of his laboratory has already led to major breakthroughs. For example, the discovery of the UM171 molecule – which multiplies stem cells in a single unit of cord blood – was the subject of a clinical trial, the first two phases of which provide great hope for developing new personalized therapies for patients suffering from AML. Your contribution could lead to practical solutions for patients suffering from AML.

To support the work of the Sauvageau laboratory is to help improve the diagnosis of patients affected by AML and to support the development of personalized treatments. It’s also to encourage the development of new therapeutic targets and the implementation of clinical trials in order for fundamental research to translate into therapeutic solutions benefiting patients.

To learn more about the project to create a Chair in Chemogenomics, please contact Anne Lebel, by telephone (514 343-6141), in person, or by email (anne.lebel@umontreal.ca).